Disease-Of-The-Quarter Club: FDA Plans 20 Patient Network Meetings Over Five Years
Executive Summary
PDUFA V framework to involve patients in the creation of the risk-benefit criteria for various diseases kicks off before the legislation is even enacted.
You may also be interested in...
Next Steps for Patient-Centered Drug Development: Room for More Input, With Limits
Patient advocates are pushing FDA to take the next step in the agency’s patient-focused drug development initiative and more directly incorporate the patient experience into regulatory decisions. While that’s a welcomed ask, FDA officials say, it’s not as easy as it looks.
Next Steps for Patient-Centered Drug Development: Room for More Input, With Limits
Patient advocates are pushing the Food & Drug Administration to take the next step in the agency’s patient-focused drug development initiative and more directly incorporate the patient experience into regulatory decisions. While that’s a welcomed ask, FDA officials say, it’s not as easy as it looks.
Patient-Focused Drug Development At 10: Where Does It Go From Here?
FDA may conduct more than the 20 required meetings by the end of fiscal year 2017, but how will the patient-focused drug development program find its place in helping generate new drugs?